Skip to main content
Clinical Trials/NCT06162403
NCT06162403
Recruiting
N/A

Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study

M.D. Anderson Cancer Center2 sites in 1 country10 target enrollmentFebruary 22, 2024

Overview

Phase
N/A
Intervention
Peripheral Nerve Stimulation
Conditions
Peripheral Nerve Stimulation
Sponsor
M.D. Anderson Cancer Center
Enrollment
10
Locations
2
Primary Endpoint
Safety and adverse events (AEs)
Status
Recruiting
Last Updated
2 months ago

Overview

Brief Summary

To learn if peripheral nerve stimulation (PNS) can help to improve pain in participants with CIPN.

Detailed Description

Primary objective: To assess Pain intensity (NRS) scores in chemotherapy induced peripheral neuropathy (CIPN) participants before and after use of peripheral nerve stimulation (PNS). Secondary objectives: To assess changes in quantitative sensory testing (QST), gait testing, and skin punch biopsy to compare the integrity of Meissner's corpuscles (MC), pain disability using the Oswestry Disability Index (ODI), pain interference using the Brief Pain Inventory (BPI), and Patient Global Impression of Change (PGIC) in CIPN patients before and after use of PNS.

Registry
clinicaltrials.gov
Start Date
February 22, 2024
End Date
December 31, 2027
Last Updated
2 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participants diagnosed with chronic (≥90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds or ionizing irradiation) of the lower extremity, seen at Pain Management Center at MD Anderson Cancer Center
  • Participants reports baseline pain ≥ 4 (0-10 scale, NRS)
  • Participants between ages 18-85 years old
  • Participants who have completed chemotherapy within the previous year at the time of enrollment

Exclusion Criteria

  • Participants with cognitive dysfunction
  • Participants with recent history (\<6 months) of drug or alcohol abuse
  • Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection
  • Participants with allergies to local anesthesia, steroids, or adhesives
  • Participants with conditions that conflict with the SPRINT PNS System Indications for Use, including Contraindications and Warnings.

Arms & Interventions

Peripheral Nerve Stimulation

Participants will be asked to have PNS leads inserted via a needle, which will provide a mild, stimulating electrical current to the effected nerves 24 hours a day for up to 60 days. Participants will have study visits during and after this time.

Intervention: Peripheral Nerve Stimulation

Outcomes

Primary Outcomes

Safety and adverse events (AEs)

Time Frame: Through study completion; an average of 1 year.

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Study Sites (2)

Loading locations...

Similar Trials